DOCSLIB.ORG

2 021 NEJM Group U.S. Media

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2 021 NEJM Group U.S. Media PRINT | DIGITAL 2021 NEJM Group Effective January 1, 2021 U.S. Media Kit Revised February 3, 2021 Clinical June | Vol. 23 No. 6 CARDIOLOGY 2014; 63:2438), knowledge has rapidly pro- • Transcatheter aortic valve replacement Oncology GUIDELINE WATCH gressed regarding the natural history of (TAVR) has received a Class I (strong) VHD; new medications have been ap- recommendation along with surgery Focused Update proved, such as the direct-acting oral anti- for patients with severe and symptom- on Management of coagulants (DOACs); and transcatheter atic aortic stenosis (AS) at high risk Valvular Heart Disease therapies have advanced. This progress for surgery and a Class IIa recommen- These guidelines touch upon infective has prompted this focused update. dation for those at intermediate risk. Update endocarditis, treatment of aortic stenosis Treatment decisions depend on indi- from NEJM Group Key Points and of primary and secondary mitral vidual patients’ risks, values, and • The Class IIa (moderate recommenda- regurgitation, and direct-acting oral preferences. tion) guideline that antibiotic prophy- anticoagulants, among other topics. laxis before dental procedures is rea- • For primary or degenerative severe Sponsoring Organizations: American sonable for patients at increased risk mitral regurgitation (MR), surgery is Heart Association and American College for infective endocarditis has now been now considered reasonable (Class IIa) of Cardiology extended to patients with transcatheter in asymptomatic patients even with Target Audience: Primary care providers prosthetic valves. ejection fraction >60% and left ven- tricular end-systolic diameter <40 mm and cardiologists (both general and sub- • DOACs are now considered reasonable if adverse progression on serial imag- specialists) who treat patients with alternatives (Class IIa) to vitamin K ing studies is evident. valvular heart disease (VHD) antagonists (VKAs) for patients • In chronic secondary (functional) Target Population: Adults with VHD with VHD and atrial fibrillation ≥ MR, chordal-sparing mitral valve re- (CHA2DS2-VASc score, 2), although Background and Objective VKAs are specifically preferred for placement is a reasonable alternative Since the 2014 publication of the last patients with mitral stenosis, who to downsized annuloplasty repair comprehensive guideline on VHD (NEJM were excluded from DOAC trials. (Class IIa). JW Cardiol Jun 2014 and J Am Coll Cardiol • The age limit for considering a me- chanical prosthesis is lowered from CONTENTS 60 to 50 (Class IIa), unless anticoagu- lation is not desired, cannot be moni- SUMMARY & COMMENT Nutrition Recommendations for a tored, or is contraindicated. ■ Endoscopic ■ The 2020 ■ Risks and Benefits ■TAVRBrachytherapy in Bicuspid vs. Tricuspid forAortic Stenosis..... 42 Healthier Heart: Getting Patients on Board ...... 45 • New data on leaflet thrombus with Management of Gastrointestinal of Breast Cancer ShouldIntermediate-Risk Non–Infarct-Related Coronary Arteries Coffee, Tea, and the Heart ....................................... 46 Also Be Revascularized After STEMI? .............. 43 Suboptimal Diet Is Associated with Excess surgical and TAVR prostheses have Lynch Syndrome Cancers Screening LargeProstate-Bore Catheters, Cancer Large Bleeding Risks...... 43 Mortality from Cardiometabolic Diseases ........ 47 prompted new anticoagulation guide- Symposium Reduced Leaflet Motion with Bioprosthetic Mixed News on Mortality lines. VKA is reasonable for ≤6 months Aortic Valves: More Details ................................. 43 for Diabetes Patients ............................................. 47 after surgical mitral and aortic valve re- Dual Antithrombotic vs. Dual Antiplatelet Hemodynamic Support After Cardiac Surgery: placement in patients at low bleeding Strategy After ACS ................................................. 44 Levosimendan Strikes Out Again ........................ 48 risk (Class IIa) and ≥3 months after Statin Use, and Possible Statin Intolerance, GUIDELINE WATCH TAVR (Class IIb; weak recommenda- After Acute MI ........................................................ 44 2017 Focused Update on Management Comparison of Two Guidelines on Statins of Valvular Heart Disease ..................................... 41 tion). Initial therapy with VKA is rea- for Primary CVD Prevention ...................................... 45 New Guidelines for the Evaluation of Adults sonable (a new Class IIa guideline) in More Evidence That Excessive Blood Pressure and Children with Suspected Syncope ............. 46 patients with suspected or confirmed Lowering Can Heighten Cardiovascular Risk ... 45 bioprosthetic valve thrombosis who are hemodynamically stable. EDITORIALLY INDEPENDENT LITERATURE SURVEILLANCE FROM NEJM GROUP Trusted. Relevant. Impactful. Table of Contents NEJM GROUP PUBLICATIONS 3Recruitment Advertising 21 NEJM Print at a Glance 4 List Rentals 21 NEJM Print 2021 ROB Full Run Rates 5 International Print Editions 21 NEJM Targeted Specialty Demos 6 NEJM Print Issue and Closing Dates 22 NEJM Cardiology Advertising Demo 6 Print Production Information 23 NEJM Endocrinology Advertising Demo 7 ROB Production Information 23 NEJM Infectious Diseases Advertising Demo 8 Insert Production Information 25 NEJM HIV/AIDS Advertising Demo 8 Insert Guidelines 25 NEJM Nephrology Advertising Demo 9 Specifications for Coverwraps 27 NEJM Neurology Advertising Demo 10 NEJM JOURNAL WATCH PRINT 28 NEJM Oncology/Hematology Advertising Demo 11 NEJM Journal Watch Print Specialty Titles 29 NEJM Pulmonary Disease and NEJM Journal Watch Production Information 30 Allergy Advertising Demo 12 NEJM Rheumatology Advertising Demo 13 NEJM.ORG AND JWATCH.ORG DIGITAL 32 NEJM Other Specialty Advertising Demos 14 Digital Display Advertising 32 High-Visibility Targeted Ad Programs 15 Introduction and Overview 32 Cover Tip Program 15 Digital Advertising on NEJM.org 34 Outsert Program 15 NEJM.org Digital Specialty Packs 35 Coverwrap Program 16 Digital Specialty Pack Rates 36 NEJM Print Special Discount Programs 17 Interactive NEJM.org Advertising Program 37 NEJM Group Update Disease State 18 NEJM Email Advertising Programs 38 Supplement Series Email Advertising Programs 39 NEJM Group Conference Update eNewsletter Series 19 Specialty-Targeted Emails 39 2021 U.S. NEJM Conference Offerings 20 Physician’s First Watch 41 Bonus Conference Distribution 20 Digital Production Information 42 Conference Discount Program 20 NEJM and NEJM Journal Watch 42 Additional Offerings 21 Digital and Email Advertising Specs 43 Market Research 21 NEJM Group Advertising Policies 44 Print and Digital Article Reprints 21 NEJM Group Contact Information 46 In print and digital, NEJM Group brings you a wide variety of advertising and sponsorship options for reaching influential specialists, from targeted demographic splits and cover tip advertising programs, to digital behavioral targeting and Image Challenge opportunities. Select any link in the Table of Contents (above) to explore NEJM Group advertising opportunities. 2021 NEJM GROUP U.S. MEDIA KIT | Trusted. Relevant. Impactful. | nejmadsales.org | Back to TOC 2 Trusted. Relevant. Impactful. Reach your HCP audience through the publications of NEJM Group to guarantee that your message is seen alongside what’s new, what’s groundbreaking, and what’s most important to practicing physicians. Choose one of the most trusted, relevant, and impactful brands because context matters now more than ever before. The New England Journal of Medicine keeps physicians at the leading edge of medical knowledge by publishing the world’s most influential, landmark research. In print and digital, NEJM brings physicians current and practical medical information — anytime and anywhere — making it the cornerstone of multichannel promotion for medical marketers. The NEW NEJM Group Print Supplement “Update” Series features timely, clinically important, and topic-relevant content adjacent to key specialty conferences — in a short-form, visually dynamic format. NEJM Journal Watch offers concise, easy-to-read summaries and expert commentary on important research from leading medical journals. The New England Journal of Medicine is the most impactful general medical journal in the world.* *Source: 2019 Journal Impact Factor, Journal Citation Reports, Clarivate, 2020. 2021 NEJM GROUP U.S. MEDIA KIT | Trusted. Relevant. Impactful. | nejmadsales.org | Back to TOC 3 NEJM Print at a Glance As the most widely read, cited, and influential general medical journal, the New England Journal of Medicine is committed to publishing reliable and leading-edge research for a worldwide multispecialty physician audience. Medical professionals rely on NEJM for its editorial independence, peer-reviewed content, and clinical relevance — and so can you! NEJM has the highest impact factor of any general medical journal,* and physicians in 12 key specialties call it one of their top two essential journals.‡ NEJM AT A GLANCE Founded 1812 Print Frequency WEEKLY Editorial INDEPENDENT Impact Factor* 74.699 U.S. Print Circulation† 110,732 NEJM ESSENTIAL IN PRINT‡ Specialty Essential Rank Internal Medicine 1 Cardiology 2 Endocrinology 1 Hematology 2 Hematology/Oncology 1 Hematology/Oncology and Oncology 1 Hematology, Hematology/Oncology, and Oncology 1 Infectious Diseases 2 Nephrology 3 Neurology 2 Oncology 2 Pulmonology 2 Rheumatology 2 *2019 Journal Impact Factor, Journal Citation Reports, Clarivate, 2020. †BPA, 7/20 ‡The Matalia Group Essential Journal Study, 2019. 2021 NEJM GROUP U.S. MEDIA
Load more

Recommended publications
  • CFP Medical Readership Information Study, 2020
    MRIStudy Medical Readership Information 2020 Results of a study of the reading patterns and preferences of Canadian family physicians conducted by the College of Family Physicians of Canada THE COLLEGE OF LE COLLÈGE DES FAMILY PHYSICIANS MÉDECINS DE FAMILLE OF CANADA DU CANADA The College of Family Physicians of Canada 2020 About the MRI Study The study was conducted during June-July, 2020. A draw for an Apple iPad was ofered as an incentive for completing the survey. The population studied was the approximately 38,000 physicians who are currently members in good standing of the College of Family Physicians of Canada. A total of 5,000 random members were invited to participate. The e-mail message to members made it clear that the survey originated with the College of Family Physicians of Canada. The invitation was sent in English and French. The invitation e-mail directed physicians to the survey questionnaire in the language of their choice, located on an independent, third-party survey site. Results were compiled using Survey Gizmo. A total of 309 family physicians completed the survey, including 279 in English and 30 in French. All responses were entirely anonymous. Medical Readership Information Study 2020 1 Notes Member survey This is a survey of members of the College of Family Physicians of Canada (CFPC), almost all of whom receive Canadian Family Physician (CFP) as a benefit of membership. This may mean that there is some degree of “halo effect” in which overall attitudes revealed in questions regarding journal readership tend to favour CFP. Journal readership patterns among francophone readers may be particularly affected.
    [Show full text]
  • NEJM JOURNAL WATCH and MORBIDITY and MORTALITY WEEKLY REPORT All Prices in US Dollars Unless Otherwise Stated
    2019-2020 Individual Subscription Pricing Agency Rate Card Prices effective from January 1, 2019 through December 31, 2020 *Please note: Subscription prices will not be raised in 2020 NEJM JOURNAL WATCH and MORBIDITY AND MORTALITY WEEKLY REPORT All Prices in US Dollars unless otherwise stated. PRINT + ONLINE, USA PRICING TITLE(S) RATES Physicians Residents Students All Other Institutions NEJM Journal Watch General Medicine Published Rate $159.00 $75.00 $75.00 $159.00 $339.00 5% Agency Remit $151.05 $71.25 $71.25 $151.05 $322.05 NEJM JW Emergency Medicine; JW Published Rate $135.00 $69.00 $69.00 $135.00 $259.00 Gastroenterology; JW Neurology; JW Women’s 5% Agency Remit $128.25 $65.55 $65.55 $128.25 $246.05 Health NEJM JW Cardiology; JW Oncology & Hematology; Published Rate $125.00 $69.00 $69.00 $125.00 $259.00 JW Pediatrics & Adolescent Medicine 5% Agency Remit $118.75 $65.55 $65.55 $118.75 $246.05 NEJM JW Infectious Diseases; JW Psychiatry Published Rate $145.00 $69.00 $69.00 $145.00 $259.00 5% Agency Remit $137.75 $65.55 $65.55 $137.75 $246.05 Morbidity and Mortality Weekly Report Published Rate $219.00 N/A N/A $219.00 $309.00 5% Agency Remit $208.05 N/A N/A $208.05 $293.55 PRINT + ONLINE, CANADA – WITH 5% GST, NO HST (In Canadian Dollars) TITLE(S) RATES Physicians Residents Students All Other Institutions NEJM Journal Watch General Medicine Published Rate C$219.00 C$104.00 C$104.00 C$219.00 C$369.00 5% Agency Remit C$208.05 C$98.80 C$98.80 C$208.05 C$350.55 NEJM JW Emergency Medicine; JW Published Rate C$195.00 C$101.00 C$101.00 C$195.00
    [Show full text]
  • WFSM Medical Resources.Pdf
    Medical resources: Everything you need from websites, podcasts, and apps You guys are awesome! Thank you for all of the medical websites, podcasts, and apps that you have recommended and submitted. I have tried to group them in a couple of ways: 1. By specialty (alphabetical) 2. By topic (alphabetical) There is a table of contents for you to reference easily find the resources in the document. I have also tried to duplicate topics that fall under multiple categories and provide short descriptions where I can. However, I would recommend looking through associated fields and topics that you might find applicable or interesting (especially for fields that cover a breadth of topics). 1 Table of contents I. Section I: Specialty……………………………………………………………………………………….….3 i. Anesthesiology………………………………………………………………………………....4 ii. Cardiology……………………………………………………………………………………..….5 iii. Dermatology…………………………………………………………………………………..…6 iv. Emergency medicine……………………………………………………………….…….7-9 v. Ear, nose, and throat (ENT) …………………………………………………………….10 vi. Family medicine………………………………………………………………………...11-12 vii. Internal medicine……………………………………………………………………….13-14 viii. Neurology…………………………………………………………………………………….…15 ix. OB/GYN…………………………………………………………………………………………..16 x. Ophthalmology……………………………………………………………………………….17 xi. Orthopedics………………………………………………………………….………………..18 xii. Pediatrics………………………………………………………………………………..….19-20 xiii. Psychiatry……………………………………………………………………………………..…21 xiv. Radiology………………………………………………………………………………….…….22 xv. Surgery……………………………………………………………………………………………23
    [Show full text]
  • Awardees & Lecturers Brochure 2012.Indd
    Berk/Fise Clinical Achievement Award The Berk/Fise Clinical Achievement Award, formerly the ACG Clinical Achievement Award, is presented to not more than one Member/Fellow of the College in any year and is made in recognition of distinguished contributions to clinical gastroenterology over a signifi cant period of time. Specifi c criteria include, in addition to a career of distinguished clinical practice of gastroenterology, contributions in patient care, clinical science, clinical education, technological innovation, and public and community service. 2012 Recipient David A. Johnson, MD, FACG Dr. David A. Johnson is Professor of Medicine and Chief of Gastroenterology at Eastern Virginia School of Medicine. Despite his primary focus on the clinical practice of gastroenterology, he has published extensively in the internal medicine/gastroenterology literature, contributing over 350 articles/chapters/abstracts in peer-reviewed journals and books. Additionally, he co-edited the American College of Physicians (ACP) book Dyspepsia and edited two GI Clinics of North America series on “Obesity Issues for Gastroenterologists” and edited the recent ACP module on CRC screening. His primary research interests are esophageal refl ux disease and colon cancer screening. He is a Past President of the American College of Gastroenterology (ACG) and served the ACG previously as Governor (VA), chair of ACG Quality Council Task Force, and member of the Educational Affairs, Publications, Constitution and Bylaws (Chair), and Nominating (Chair) committees. Additionally since inception, he has served on the executive committee and is Treasurer of the ACG/ASGE GI Quality Improvement Consortium (GIQuIC) and the executive committee for the GI Political Action Committee (GIPAC).
    [Show full text]
  • Obsessive-Compulsive Disorder: Diagnosis and Management JILL N
    Obsessive-Compulsive Disorder: Diagnosis and Management JILL N. FENSKE, MD, and THOMAS L. SCHWENK, MD, University of Michigan Medical School, Ann Arbor, Michigan Obsessive-compulsive disorder is an illness that can cause marked distress and disability. It often goes unrecognized and is undertreated. Primary care physicians should be familiar with the various ways obsessive-compulsive disorder can present and should be able to recognize clues to the presence of obsessions or compulsions. Proper diagnosis and education about the nature of the disorder are important first steps in recovery. Treatment is rarely curative, but patients can have significant improvement in symptoms. Recommended first-line therapy is cog- nitive behavior therapy with exposure and response prevention or a selective serotonin reuptake inhibitor. The medication doses required for treatment of obsessive-compulsive disorder are often higher than those for other indications, and the length of time to response is typi- cally longer. There are a variety of options for treatment-resistant obsessive-compulsive disorder, including augmentation of a selec- tive serotonin reuptake inhibitor with an atypical antipsychotic. ECK Obsessive-compulsive disorder is a chronic condition with a high rate B of relapse. Discontinuation of treatment should be undertaken with oan caution. Patients should be closely monitored for comorbid depression and suicidal ideation. (Am Fam Physician. 2009;80(3):239-245. Copy- right © 2009 American Academy of Family Physicians.) ILLUSTRATION BY J ▲ Patient information: bsessive-compulsive disorder from obsessions and compulsions.2 OCD A handout on obsessive- (OCD) is a neuropsychiatric dis- interferes with work performance, social compulsive disorder, written by the authors order characterized by recurrent interactions, and family relationships.
    [Show full text]
  • BMJ in the News Is a Weekly Digest of Journal Stories, Plus Any Other News
    BMJ in the News is a weekly digest of journal stories, plus any other news about the company that has appeared in the national and a selection of English-speaking international media. A total of 22 journals were picked up in the media last week (13-19 May) - our highlights ​ ​ include: ● A paper published in The BMJ linking glucosamine supplements with a lower risk of ​ ​ cardiovascular disease was covered extensively, including The Independent, The ​ New York Times and The Telegraph. ​ ​ ● Research published in Gut revealing that bowel cancer is rising among younger ​ ​ adults in Europe was picked up by inews, HuffPost UK and BBC News (+ tweeted by ​ ​ ​ ​ ​ ​ Victoria Derbyshire). ● A study published in Tobacco Control suggesting that the Tobacco display ban has ​ ​ reduced the risk of children smoking made headlines in BBC News, ITV News and ​ ​ Daily Mail. PRESS RELEASES The BMJ | British Journal of Sports Medicine ​ ​ ​ Gut EXTERNAL PRESS RELEASES The BMJ | Tobacco Control ​ ​ OTHER COVERAGE The BMJ | Annals of the Rheumatic Diseases ​ ​ BMJ Case Reports | BMJ Global Health ​ ​ BMJ Open | BMJ Open Diabetes Research & Care ​ ​ BMJ Open Gastroenterology | BMJ Open Sport & Exercise Medicine ​ ​ British Journal of Ophthalmology | Heart ​ ​ Injury Prevention | Journal of Epidemiology & Community Health ​ ​ Journal of Medical Ethics | Journal of Neurology, Neurosurgery & Psychiatry ​ ​ ​ Occupational & Environmental Medicine | Open Heart ​ ​ Regional Anesthesia & Pain Medicine | RMD Open ​ ​ Sexually Transmitted Infections T he BMJ Research: Association of habitual glucosamine use with risk of cardiovascular ​ disease: prospective study in UK Biobank (PR) ​ Taking joint supplements could help lower risk of heart disease and stroke The Independent ​ 14/05/2019 Glucosamine Tied to Heart Benefits The New York Times 14/05/2019 ​ Joint supplements could reduce the chance of early heart death by a fifth The Telegraph ​ 14/05/2019 Also in: Daily Mail, The Irish Times, The Sun,The Herald, U.S.
    [Show full text]
  • Does Prompt Tympanostomy Improve Speech, Language, and Cognitive
    Arch Dis Child 2004;89:87–88 87 Arch Dis Child: first published as on 7 January 2004. Downloaded from Selections from Journal Watch Pediatrics and Adolescent Medicine Copyright E 2004 Massachusetts Medical Society. All rights reserved. Please visit the ADC website (www.archdischild.com) full-term infants, children, and adolescents without neurologic for links to these articles – many to full text. impairment. Here are some highlights of the guideline for infants: Definition: GER is the passage of gastric contents into the esophagus. Gastroesophageal reflux disease (GERD) refers to symptoms or complications of GER, including, in infants, irritability, poor weight gain, food refusal, and such respiratory disorders as ....................................................................... asthma and apnea. Diagnosis: Upper gastrointestinal series is neither sensitive nor Does prompt tympanostomy improve specific for diagnosis. Esophageal pH monitoring is precise in speech, language, and cognitive develop- making the diagnosis and assessing the effectiveness of treatment. ment? c Pediatricians have been haunted by concerns that Endoscopy with biopsy is necessary to confirm the diagnosis of chronic middle-ear effusion (MEE) – prevalent during the critical reflux with esophagitis. period for speech and language development – causes later Management: Approaches should be tailored to the specific impairment in learning and language skills. Although current history and severity of symptoms. Milk protein allergy can present as practice sanctions placement of tympanostomy tubes for MEE vomiting and cause GERD with esophagitis but is uncommon. A 1- persisting 3 months or longer, evidence to support this treatment to 2-week trial of hypoallergenic formula is recommended. is limited. In this long-term, prospective study, researchers enrolled Although thickening the formula does not reduce reflux index 6350 infants (age range, 2 to 61 days) who were regularly scores, it does reduce the occurrence of vomiting.
    [Show full text]
  • Potential Adverse Effects of Proton Pump Inhibitors in the Elderly
    Potential Adverse Effects of Proton Pump lnhibitors in the Elderly Ami Kapadia, MD, Daisy Wynn, MD, and Brooke Salzman, MD Introduction dence of side effects is similar to placebo, which is less than Since the introduction of omeprazole in 1989, proton 5%.’0 The most common side effects reported are headache, pump inhibitors (PPIs) have become one of the most com- diarrhea, abdominal pain, and nausea. The etiology of these monly prescribed classes of medications in the world. In side effects, particularly diarrhea, may be related to alter- 2007, PPI sales in the United States ~vere in excess of$1 ! bil- ations in gut flora caused by acid suppression50 The only lion5 Esomeprazole and lansoprazole both ranked among contraindication to the use of PPIs is a known history of the top five drugs sold in the United States in 20075 hypersensitivity to this class of medications. PPIs do not Overall, with their high safety profile and demonstrated require dosage adjustment in renal or hepatic dysfunction. efficacy, PPIs represent a major advance in the treatment of acid-related disorders ranging from peptic ulcer disease to Indications and Approved Uses erosive esophagitis. However, it has been shown that PPIs are PPls are accepted for the treatment and remission mainte- often misused and overused, which may have significant nance of acute gastric and duodenal ulcers, symptomatic gas- -7 implications? With the widespread and frequent long-term troesophageal reflux disease (GERD), erosive esopha~gitis, use of PPls, several adverse effects have come to light that pathological hypersecretory conditions such as Zollinger- may call for more selective prescribing practices, particularly Ellison syndrome, nonsteroidal anti-inflammatory drug- in older adults who may be more vulnerable and likely to induced gastric ulcers, and eradication of Helicoba/terpy/ori suffer the consequences of such adverse effects.
    [Show full text]
  • Curriculum Vitae Ann J
    Curriculum Vitae Ann J. Davis, M.D. Page 1 CURRICULUM VITAE Date Prepared: October 1, 2009 Updated: March 2014 ADDRESS: Office: Home: (b) (6) Geisel School of Medicine at Dartmouth (formerly Dartmouth Medical School) (b) (6) Office of Student Affairs Remsen 7010 (b) (6) Hanover, New Hampshire 03755 Phone: 603-650-1833 Email: [email protected] EDUCATION 1980 Medical Degree Obstetrics and Gynecology University of Oregon Medical School Portland, Oregon 1975 Bachelor of Science General Science/ Oregon State University Biochemistry Corvallis, Oregon POSTDOCTORAL TRAINING 1980 -1981 Internship Obstetrics and Gynecology Medical College of Georgia Augusta, Georgia 1983 - 1986 Resident Obstetrics and Gynecology Medical College of Georgia Augusta, Georgia 1985 Medical Rotation Pediatric and Adolescent Professor Sir John Dewhurst Gynecology London, England 1987 - 1988 Fellowship Pediatric and Adolescent Children’s Hospital Gynecology, Department of Harvard Medical School Surgery Boston, Massachusetts FACULTY ACADEMIC APPOINTMENTS 1986 – 1987, Assistant Professor Obstetrics and Gynecology Tufts University School of Medicine 1997 – 2003 Boston, Massachusetts 1986 – 1995 Assistant Professor Obstetrics and Gynecology, Tufts University School of Medicine Pediatrics Boston, Massachusetts 1995 – 1996, Associate Professor Obstetrics and Gynecology, Tufts University School of Medicine 2003 – 2007 Pediatrics Boston, Massachusetts 2007-6/09 Professor Obstetrics and Gynecology, Tufts University School of Medicine Pediatrics Boston, Massachusetts Curriculum
    [Show full text]
  • Guideline Watch 2019
    GUIDELINE WATCH 2019 Summaries and highlights of the most important new clinical guidelines to inform your practice June 2019 nejm journal watch Dear Reader, Cardiology Emergency Medicine Clinical guidelines inform practice standards and establish quality Gastroenterology measures. In pursuing our mission to improve patient care and General Medicine foster professional development, NEJM Journal Watch seeks to help Hospital Medicine you keep up with the guidelines most important to your practice. Infectious Diseases Our 90 clinician-editors regularly survey more than 250 medical Neurology journals to identify the latest critical information. As part of this Oncology and Hematology effort, we evaluate a broad range of clinical guidelines in a variety Pediatrics and Adolescent Medicine of disciplines, choose those with the most clinical impact, and Psychiatry summarize them, highlighting key points and identifying what’s Women’s Health new in a feature called Guideline Watch. This collection of Guideline Watches, published in the last 6 months, covers a range of guidelines, from updated guidance by the Infectious Diseases Society of America on the diagnosis, treatment, chemo- prophy laxis, and institutional outbreak management of seasonal influenza to the latest recommendations by the American College of Cardiology/American Heart Association Task Force on managing blood cholesterol. The common denominator is their relevance to and implications for clinical practice. The topics in this collection span outpatient and inpatient medicine and primary care and sub- specialty perspectives. We believe that you’ll find something of interest in each of them. We hope you enjoy this compilation and find it useful for providing the best and most responsible patient care, and we invite you to interact with us at JWatch.org.
    [Show full text]
  • NEW ENGLAND JOURNAL of MEDICINE and NEJM JOURNAL WATCH INDIVIDUAL SUBSCRIPTION AGENCY INFORMATION FACT SHEET (Valid for Years 2018 and 2019)
    NEW ENGLAND JOURNAL OF MEDICINE AND NEJM JOURNAL WATCH INDIVIDUAL SUBSCRIPTION AGENCY INFORMATION FACT SHEET (Valid for years 2018 and 2019) PAYMENT OPTIONS: For all payment options, please be sure to include customer name and account number. Send an email to [email protected] with any questions. Checks: Please make checks payable to “New England Journal of Medicine” and mail to: NEJM Group PO Box 549140 Waltham, MA 02454-9140 USA Credit card: Credit card orders may be sent to our secure fax line at 1-781-893-0413. Wire transfer: To ensure your account is credited promptly, please send an email to [email protected], noting the amount of the wire transfer, the date sent, and the customer name and account number. Bank: Bank of America, 100 Federal Street, Boston, MA 02110, USA Account Name: Massachusetts Medical Society New England Journal of Medicine Account Number: 510-11950 ABA Number: 0260-0959-3 Swift Code: BOFAUS3N ACH transfer: To ensure your account is credited promptly, please send an email to mailto:[email protected] noting the amount of the ACH transfer, the date sent, and the customer name and account number. Bank: Bank of America, 100 Federal Street, Boston, MA 02110, USA Account Name: Massachusetts Medical Society New England Journal of Medicine Account Number: 0000510-11950 Routing Transit No.: 011000138 TAXES: Subscription agents are responsible for collecting and remitting applicable taxes to the appropriate tax authorities, except in Canada. For orders from customers in Canada, GST/HST, as applicable, should be included with subscription and renewal payments. AGENCY DISCOUNT: The standard agency discount for new and renewal individual subscriptions for all New England Journal of Medicine and Journal Watch products (including nejm.org and jwatch.org) is 5%.
    [Show full text]
  • UTSW Internal Medicine Journal Watch (March 2014) Table Of
    UTSW Internal Medicine Journal Watch (March 2014) Table of Contents Infectious Diseases ............................................................................................................................... 2 Cardiology ................................................................................................................................................ 3 Nephrology .............................................................................................................................................. 3 General Internal Medicine ................................................................................................................. 4 Palliative Care ........................................................................................................................................ 4 Geriatrics .................................................................................................................................................. 5 Additional interesting reads based on specialty ....................................................................... 5 Hematology/Oncology ..................................................................................................................................... 5 1 Infectious Diseases 1. Lawitz E, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomized, phase 2 trial. Lancet 2014 Feb 8; 383 (9916):
    [Show full text]